Simvastatin-induced apoptosis in osteosarcoma cells: A key role of rhoa-ampk/p38 mapk signaling in antitumor activity

Walied A. Kamel, Eiji Sugihara, Hiroyuki Nobusue, Sayaka Yamaguchi-Iwai, Nobuyuki Onishi, Kenta Maki, Yumi Fukuchi, Koichi Matsuo, Akihiro Muto, Hideyuki Saya, Takatsune Shimizu

研究成果: Article査読

60 被引用数 (Scopus)


Osteosarcoma is the most common type of primary bone tumor, novel therapeutic agents for which are urgently needed. To identify such agents, we screened a panel of approved drugs with a mouse model of osteosarcoma. The screen identified simvastatin, which inhibited the proliferation and migration of osteosarcoma cells in vitro. Simvastatin also induced apoptosis in osteosarcoma cells in a manner dependent on inhibition of the mevalonate biosynthetic pathway. It also disrupted the function of the small GTPase RhoA and induced activation of AMP-activated protein kinase (AMPK) and p38 MAPK, with AMPK functioning upstream of p38 MAPK. Inhibitors of AMPK or p38 MAPK attenuated the induction of apoptosis by simvastatin, whereas metformin enhanced this effect of simvastatin by further activation of AMPK. Although treatment with simvastatin alone did not inhibit osteosarcoma tumor growth in vivo, its combination with a fat-free diet induced a significant antitumor effect that was enhanced further by metformin administration. Our findings suggest that simvastatin induces apoptosis in osteosarcoma cells via activation of AMPK and p38 MAPK, and that, in combination with other approaches, it holds therapeutic potential for osteosarcoma.

ジャーナルMolecular cancer therapeutics
出版ステータスPublished - 2017 1月

ASJC Scopus subject areas

  • 腫瘍学
  • 癌研究


「Simvastatin-induced apoptosis in osteosarcoma cells: A key role of rhoa-ampk/p38 mapk signaling in antitumor activity」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。